Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug
Portfolio Pulse from
Regeneron has received a positive opinion from the CHMP for conditional marketing authorization of its drug linvoseltamab, aimed at treating adults with relapsed and refractory multiple myeloma.
March 03, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron has received a positive opinion from the CHMP for its drug linvoseltamab, which is a step towards conditional marketing authorization for treating multiple myeloma.
The positive CHMP opinion is a significant regulatory milestone for Regeneron, indicating potential future revenue from linvoseltamab if it receives full marketing authorization. This news is likely to positively impact REGN's stock price in the short term as it reflects progress in their drug pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100